Yanping Hu

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

Jie Wang, Shun Lü, Xinmin Yu et al. · JAMA Oncology · 2021 · 381 citations · Full text

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Shun Lü, Jie Wang, Yan Yu et al. · Journal of Thoracic Oncology · 2021 · 264 citations · Full text

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations

Shun Lü, Xiaorong Dong, Hong Jian et al. · Journal of Clinical Oncology · 2022 · 253 citations · Full text

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial

Shun Lü, Lin Wu, Hong Jian et al. · The Lancet Oncology · 2022 · 227 citations

Oncology, First Interim Results, Bevacizumab Biosimilar Ibi305 +10

Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.

Yanping Hu, Gabriele Cherton-Horvat, Visia Dragowska et al. · PubMed · 2003 · 220 citations

Tumor Biology, Drug Targeting, Oncogenic Agent +15